Home » Newsletters » BioWorld Science

BioWorld Science

May 15, 2007

View Archived Issues

Phase III data on difluprednate ophthalmic emulsion in ophthalmic conditions

HDAC inhibition restores learning and memory in a mouse model of neurodegeneration

Long-term inhibition of choroidal neovascularization with engineered ZFP transcription factor

Safety established for SNJ-1656 in the treatment of glaucoma

Phase I/II trial cleared for CAM-2032 leuprolide depot

Nippon Shinyaku resolves joint development agreement for TRK-091

AERAS-402 studied for TB in new South African study

Phase I trial planned for CALAA-01 in advanced solid tumors

BF-37 enters phase II study in atopic dermatitis

NCI seeks FDA approval to study Oncolytics' Reolysin in phase II for melanoma

GlaxoSmithKline returns rights to Futura for MED-2002 for ED

Study of dextromethorphan in involuntary emotional expression disorder advances / News in Context

Study reveals potential of alemtuzumab in sporadic inclusion body myositis

PTC-124 active in Duchenne muscular dystrophy due to a nonsense mutation

Long-term suppression of chorea seen with tetrabenazine in Huntington's disease

New antithrombotic agents disclosed in recent Toray patent

Recent patents divulge novel analgesic agents

Novel opioid receptor antagonists emerge from Adolor R&D

Recent Chugai and sanofi-aventis patents describe new treatment options for diabetes

FDA approves first nebulized formoterol fumarate for emphysema and COPD

FDA approves Fosamax Plus D with higher vitamin D content

Wyeth Pharmaceuticals seeks EMEA approval of subcutaneous methylnaltrexone

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...